Pre-made Rozibafusp benchmark antibody ( Whole mAb Fusion, anti-ICOS therapeutic antibody, Anti-AILIM/CD278/CVID1 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Rozibafusp biosimilar, Whole mAb Fusion, Anti-ICOS Antibody: Anti-AILIM/CD278/CVID1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Rozibafusp alfa (previously AMG 570) is being developed by Amgen and AstraZeneca, for the treatment of systemic lupus erythematosus (SLE) and rheumatoid.
| Products Name (INN Index) | Pre-Made Rozibafusp biosimilar, Whole mAb Fusion, Anti-ICOS Antibody: Anti-AILIM/CD278/CVID1 therapeutic antibody |
|---|---|
| INN Name | Rozibafusp |
| Target | ICOS |
| Format | Whole mAb Fusion |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | 6x4t:BE:DF |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | Amgen |
| Conditions Approved | NA |
| Conditions Active | Systemic lupus erythematosus |
| Conditions Discontinued | Rheumatoid arthritis |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | ICOS |
| Package |
